Literature DB >> 23598574

Evidence-based therapy prescription in high-cardiovascular risk patients: the REACT study.

Otávio Berwanger1, Luiz Alberto Piva e Mattos, José Fernando Vilela Martin, Renato Delascio Lopes, Estevão Lanna Figueiredo, Daniel Magnoni, Dalton Bertolim Precoma, Carlos Alberto Machado, Jorge Ilha Guimarães, Jadelson Pinheiro de Andrade.   

Abstract

BACKGROUND: Data on outpatient care provided to patients at high cardiovascular risk in Brazil are insufficient.
OBJECTIVE: To describe the profile and document the clinical practice of outpatient care in patients at high cardiovascular risk in Brazil, regarding the prescription of evidence-based therapies.
METHODS: Prospective registry that documented the ambulatory clinical practice in individuals at high cardiovascular risk, which was defined as the presence of the following factors: coronary artery disease, cerebrovascular and peripheral vascular diseases, diabetes, or those with at least three of the following factors: hypertension, smoking, dyslipidemia, age > 70 years, family history of coronary artery disease, chronic kidney disease or asymptomatic carotid artery disease. Basal characteristics were assessed and the rate of prescription of pharmacological and non-pharmacological interventions was analyzed.
RESULTS: A total of 2364 consecutive patients were included, of which 52.2% were males, with a mean age of 66.0 years (± 10.1). Of these, 78.3% used antiplatelet agents, 77.0% used statins and of patients with a history of myocardial infarction, 58.0% received beta-blockers. Concomitant use of these three classes of drugs was 34%; 50.9% of hypertensive, 67% of diabetic and 25.7% of dyslipidemic patients did not achieve the goals recommended by guidelines. The main predictors of prescription therapies with proven benefit were centers with a cardiologist and history of coronary artery disease.
CONCLUSION: This national and representative registry identified important gaps in the incorporation of therapies with proven benefit, offering a realistic outlook of patients at high cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23598574     DOI: 10.5935/abc.20130062

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  5 in total

1.  Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial.

Authors:  M Julia Machline-Carrion; Rafael Marques Soares; Lucas Petri Damiani; Viviane Bezerra Campos; Bruna Sampaio; Francisco H Fonseca; Maria Cristina Izar; Celso Amodeo; Octávio Marques Pontes-Neto; Juliana Yamashita Santos; Samara Pinheiro do Carmo Gomes; José Francisco Kerr Saraiva; Eduardo Ramacciotti; Pedro Gabriel de Melo Barros E Silva; Renato D Lopes; Nilton Brandão da Silva; Hélio Penna Guimarães; Leopoldo Piegas; Airton T Stein; Otávio Berwanger
Journal:  JAMA Cardiol       Date:  2019-05-01       Impact factor: 14.676

2.  Implementation of multicenter records in the therapeutic cardiovascular assessment in Brazil.

Authors:  Luiz Felipe P Moreira
Journal:  Arq Bras Cardiol       Date:  2013-12       Impact factor: 2.000

Review 3.  Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis.

Authors:  A Marzà-Florensa; E Drotos; P Gulayin; D E Grobbee; V Irazola; K Klipstein-Grobusch; I Vaartjes
Journal:  Glob Heart       Date:  2022-06-08

4.  Evaluation of 1-Year Follow-up of Patients Included in the Registry of Clinical Practice in Patients at High Cardiovascular Risk (REACT).

Authors:  Pedro Gabriel Melo de Barros E Silva; Otavio Berwanger; Dalton Bertolim Precoma; Margaret Assad Cavalcante; José Fernando Vilela-Martin; Estêvão Lanna Figueiredo; Renato Delascio Lopes; Luiz Carlos Bodanese; Jorge Ilha Guimarães; Jadelson Pinheiro de Andrade; Angelo Amato Vincenzo de Paola; Marcus Vinicius Bolivar Malachias; Luiz Alberto Piva E Mattos; Fernando Bacal; Oscar Pereira Dutra
Journal:  Arq Bras Cardiol       Date:  2021-01       Impact factor: 2.000

5.  Use of evidence-based interventions in acute coronary syndrome - Subanalysis of the ACCEPT registry.

Authors:  Ricardo Wang; Fernando Carvalho Neuenschwander; Augusto Lima Filho; Celsa Maria Moreira; Elizabete Silva dos Santos; Helder Jose Lima Reis; Edson Renato Romano; Luiz Alberto Piva e Mattos; Otávio Berwanger; Jadelson Pinheiro de Andrade
Journal:  Arq Bras Cardiol       Date:  2014-02-17       Impact factor: 2.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.